Earlier this year, French medical technology company Carmat broke ground by implanting an artificial heart into Georges Pompidou, a 76-year-old patient suffering from heart failure. However, after 75 days of wearing the device, Pompidou passed away. On Monday, Carmat announced that a second patient suffering from chronic heart failure was successfully fitted with an artificial heart while two more patients are currently undergoing clinical trials.

“We would like to wholeheartedly thank our investigation centers’ clinical teams for their involvement alongside us, and today especially the experienced teams at the Nantes University Hospital,” Carmat CEO Marcello Conviti said in a statement. “This milestone has been made possible by their trust, as well as that of our staff, partners, and shareholders.”

Carmat’s artificial heart is a combination of synthetic and natural materials intended to simulate the function of a human heart via heart muscle contractions and sensors that adapt to the blood flow caused by the patient’s movements. This bioprosthetic organ has also been designed to cut down on the side effects associated with heart transplants, including blood clots and rejection. Although its power source comes from lithium-ion batteries worn on the outside of the body, bovine tissue forms the inner surface that comes into contact with human blood, whereas plastic tends to cause blood clotting.

Despite Pompidou’s death less than three months after the first artificial heart transplant, Carmat researchers said the results were positive, seeing as the estimated survival rate for the patient was 30 days. They now intend to follow the progress of this newest artificial heart recipient for 30 days before enrolling 20 more heart failure patients during the next stage of clinical trials. The unidentified patient received the artificial heart on Aug. 5 at a hospital in Nantes.

Breaking into a potential $22 billion artificial heart market in the United State and Europe, Carmat said its device will be priced at between 140,000 euros ($181,000) and 180,000 euros ($233,000). Carmat’s competitors in the U.S. currently include SynCardia Systems and Abiomed. One patient that received a SynCardia artificial heart lived for four years. Abiomed’s titanium and polyurethane artificial heart AbioCor is also available for patients ineligible for heart transplants.